PDCD1 and breast carcinoma: Currently, zanidatamab is being tested in (i) a phase 2b trial (NCT04466891, HERIZON-BTC-01) enrolling patients with advanced HER2-overexpressing BTC following progression to the first-line gemcitabine-based regimen, (ii) in a phase 2a trial (NCT04224272) in combination with both the cyclin-dependent kinase 4/6 inhibitor (iCDK4/6) palbociclib and the anti-hormone receptor (HR) fulvestrant in patients with advanced HER2+/HR+ breast cancer, and (iii) in a phase 1b/2 trial (NCT04276493) in combination with the anti-PD-1 tislelizumab.